EBITDA* | FY 2020E | FY 2021E |
---|---|---|
Consensus | 1,914 | 2,178 |
Max | 2,120 | 2,391 |
Min | 1,536 | 1,846 |
Target price (TP)* | GBp |
---|---|
Consensus | 407 |
Max | 620 |
Min | 250 |
Recommendations of analysts
Broker | Date | Recommendation | Target price, GBp |
---|---|---|---|
Goldman Sachs | 07-Sep-20 | sell | 290 |
ATON | 1-Sep-20 | hold | 380 |
JP Morgan | 19-Aug-20 | hold | 500 |
Sberbank CIB | 24-Sep-20 | hold | 369 |
BCS | 16-Sep-20 | hold | 410 |
Rencap | 16-Sep-20 | buy | 620 |
Morgan Stanley | 23-Sep-20 | hold | 320 |
Citi | 08-Jun-20 | sell | 250 |
VTB Capital | 01-May-20 | buy | 460 |
Veles Capital | 30-Jun-20 | buy | 527 |
* Consensus EBITDA and TP are calculated on the basis of the last six months of broker reports, while eliminating the highest and lowest estimates to calculate the average.
Last update: 28.09.2020
This document has been issued by EVRAZ plc for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various independent analysts regarding EVRAZ’s revenues, earnings and business development. Such estimates and forecasts cannot be independently verified by reason of their subjective nature. EVRAZ plc gives no guarantee, representation or warranty and is not responsible or liable in any way as to the accuracy and completeness of this document.